A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

NCT01600963 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped PhIII program revised; TMC207-C210 cancelled

Conditions

Multi-drug Resistant Tuberculosis

Interventions

DRUG: Arm A Double-blind Phase: TMC207
DRUG: Arm B Double-blind Phase: Placebo
DRUG: Treatment Failure During Double-blind Phase: TMC207
DRUG: Treatment Failure During Follow-up Phase: TMC207

Sponsor

Janssen Infectious Diseases BVBA